Pfizer to Pursue Lyme Disease Vaccine Approval Despite Late-Stage Trial Setback

Pfizer announced on Monday it will seek regulatory approval for its investigational Lyme disease vaccine, despite the fact that a late-stage clinical trial did not meet its pre-defined statistical goals. The decision comes as the pharmaceutical giant reported strong efficacy data, with the vaccine demonstrating over 70% effectiveness in preventing Lyme disease.

Trial Results and Efficacy

The Phase 3 VALOR trial, conducted in collaboration with Valneva SE, showed the vaccine reduced the rate of confirmed Lyme disease cases by more than 70% in individuals aged five years and above compared to a placebo. However, the trial did not accrue enough Lyme disease cases to reach the pre-determined statistical criterion for success.

“The efficacy shown in the VALOR study of more than 70% is highly encouraging and creates confidence in the vaccine’s potential to protect against this disease that can be debilitating,” said Annaliesa Anderson, Pfizer’s Chief Vaccines Officer, in a statement.

Lyme Disease: A Persistent Public Health Challenge

Lyme disease is a bacterial infection transmitted to humans through the bite of infected ticks. It can lead to a range of symptoms, including arthritis, muscle weakness, and pain. Approximately half a million Americans are diagnosed with or treated for Lyme disease annually, according to estimates from the Centers for Disease Control and Prevention.

Currently, there is no human vaccine available in the United States. A previous Lyme disease vaccine, LYMErix, was withdrawn from the market in 2002 due to public safety concerns and declining demand.

Vaccine Mechanism and Future Outlook

The Pfizer-Valneva vaccine targets the outer surface protein A (OspA) of the bacteria responsible for Lyme disease. The vaccine works by prompting the body to create antibodies that, when transferred to a tick, prevent the bacterium from being transmitted to a human. The vaccination schedule involves three initial shots followed by a booster dose the subsequent year.

While the vaccine is not expected to be a major revenue driver for Pfizer – Valneva estimates peak annual sales of over $1 billion – it represents a significant step forward in addressing a critical public health need. Pfizer anticipates submitting the data to regulatory authorities for review.